Antimicrobials · Aminoglycosides
The facts most likely to be tested
Press 1–5 to rate · ↑↓ to navigate
Amikacin is an aminoglycoside that exerts its bactericidal effect by binding to the 30S ribosomal subunit, inhibiting bacterial protein synthesis.
The primary mechanism of nephrotoxicity associated with amikacin is acute tubular necrosis (ATN), typically presenting as a rise in serum creatinine.
Amikacin carries a significant risk of ototoxicity, which manifests as irreversible sensorineural hearing loss or vestibular dysfunction.
The clinical use of amikacin is primarily reserved for multidrug-resistant Gram-negative infections, including Pseudomonas aeruginosa.
Amikacin exhibits concentration-dependent killing and a significant post-antibiotic effect, supporting the use of once-daily dosing regimens.
The aminoglycoside class, including amikacin, can cause neuromuscular blockade, which is particularly dangerous in patients with myasthenia gravis.
Therapeutic drug monitoring is mandatory for amikacin to prevent toxicity, specifically targeting peak levels for efficacy and trough levels to minimize renal damage.
Vignette unlocked
A 62-year-old male with a history of cystic fibrosis is hospitalized for a severe pulmonary exacerbation caused by multidrug-resistant Pseudomonas aeruginosa. He is started on intravenous amikacin. On day 6 of therapy, the patient reports new-onset tinnitus and a sensation of vertigo. Laboratory studies reveal a serum creatinine increase from 0.9 mg/dL to 1.4 mg/dL. His trough amikacin level is found to be significantly elevated.
Which of the following is the most likely mechanism of the patient's current adverse clinical findings?
Accumulation of the drug leading to ototoxicity and acute tubular necrosis
The patient is exhibiting classic signs of aminoglycoside toxicity (ototoxicity and nephrotoxicity) due to elevated trough levels, which necessitates dose adjustment or discontinuation.
Full handout
High yield triage
Classification
Aminoglycoside; broad-spectrum bactericidal agent.
Indications
Severe Gram-negative infections, including Pseudomonas aeruginosa.
Mechanism of Action
Binds 30S ribosomal subunit to inhibit protein synthesis.
Side Effects
Ototoxicity, nephrotoxicity, and neuromuscular blockade.
Contraindications / Monitoring
Myasthenia gravis; monitor serum trough levels and creatinine.
Full handout
Mechanism of Action
Amikacin irreversibly binds to the 30S ribosomal subunit, causing misreading of the genetic code and inhibition of protein synthesis. This leads to the production of non-functional proteins and cell death. It is primarily effective against aerobic Gram-negative bacilli.
Unique Properties
Amikacin is the most resistant aminoglycoside to bacterial modifying enzymes. This makes it the drug of choice when other aminoglycosides like gentamicin fail due to resistance patterns.
Indications
Used for serious nosocomial infections, including sepsis, pneumonia, and complicated urinary tract infections. It is often used in combination with a beta-lactam for synergistic coverage of Pseudomonas aeruginosa.
Pharmacokinetics
Excreted unchanged by the kidneys via glomerular filtration. It exhibits concentration-dependent killing and a significant post-antibiotic effect, allowing for once-daily dosing regimens.
Side Effects & Adverse Events
The most feared adverse effects are irreversible ototoxicity (vestibular and auditory) and acute tubular necrosis (nephrotoxicity). Rapid infusion can trigger neuromuscular blockade, leading to respiratory paralysis. Monitor for tinnitus or vertigo as early warning signs.
Contraindications
Myasthenia gravis is an absolute contraindication due to the risk of precipitating severe muscle weakness. Use with extreme caution in patients with pre-existing renal impairment or those taking other nephrotoxic drugs like vancomycin or amphotericin B.
Monitoring
Requires therapeutic drug monitoring to prevent toxicity. Measure peak levels for efficacy and trough levels to prevent accumulation. Monitor serum creatinine and BUN daily to assess renal function.
Clinical Pearls
Always suspect aminoglycoside toxicity if a patient develops new-onset tinnitus or rising creatinine during therapy. Remember that nephrotoxicity is usually reversible, whereas ototoxicity is often permanent.